NYSE:ELANPharmaceuticals
A Look At Elanco Animal Health’s Valuation After Befrena Approval And Pet Care Growth Focus
Conference spotlight and product news put Elanco in focus
Elanco Animal Health (ELAN) is drawing fresh attention after securing U.S. Department of Agriculture approval for its new canine dermatitis treatment, Befrena, and outlining its plans ahead of its J.P. Morgan Healthcare Conference appearance.
See our latest analysis for Elanco Animal Health.
Those product updates and the J.P. Morgan appearance come as Elanco’s share price sits at $24.45, with a 30 day share price return of 14.84% and a...